A Phase 2 interventional study of Vedolizumab in Ulcerative Colitis and Crohn's Disease, sponsored by Takeda. Completed at 88 sites in 11 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-12-21.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing vedolizumab in Colitis, Ulcerative — 5 open to participants now, 9 under way, 6 of them phase 3. vedolizumab · Colitis, Ulcerative.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, this one is the 21st largest by enrollment, is one of 8 that started in 2017, is one of 5 in phase 2, and was the 17th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →5 of the 38 studies testing vedolizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
Takeda · Sites in United States, Australia, Belgium and 15 more countries
Ages 2+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
vedolizumab: first FDA approval 2014 (ENTYVIO), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 8 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 89 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 110 across the 38 interventional studies. Of the 23 that completed or were terminated, 16 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 38 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
68 studies in Colitis, Ulcerative by Takeda: 6 open now, 10 under way, 5 of them phase 3. Of 54 finished, 35 (65%) have results posted.
Among the 68 studies in Colitis, Ulcerative by Takeda, this one is the 29th largest by enrollment of the 43 interventional ones that give a count, is one of 8 that started in 2017, is one of 10 in phase 2, and was the 30th registered.
Takeda’s Colitis, Ulcerative studies by the year they started, since 2003.
4 of the studies testing vedolizumab in Colitis, Ulcerative that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT03221036Phase 3TakedaEfficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis | 2027-09-24 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06095128TakedaA Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC) | 2027-07-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 38 studies testing vedolizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Takeda’s 68 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate vedolizumab pharmacokinetics (PK), safety and tolerability in pediatric participants with moderately to severely active UC or CD.
The drug being tested in this study is called vedolizumab. Vedolizumab is being tested to treat pediatric participants who have moderately to severely active UC or CD. This study will look at the PK, efficacy, immunogenicity, safety, and tolerability in participants who take vedolizumab.
The study will enroll approximately 80 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of the two dose regimens (high or low) per weight group >=30 kg and 10 kg to \<30 kg in ratio 1:1-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):
All participants will be administered vedolizumab via IV infusion. Participants assigned to the low dose group who do not achieve clinical response (based on pediatric UC/CDAI) at Week 14 will receive the high dose (that is, 300 mg for participants >=30 kg baseline weight and 200 mg for participants 10 kg to \<30 kg baseline weight) of vedolizumab IV at Week 14. Participants assigned to the high dose group who had not achieved clinical response continued on the same blinded high dose at Week 14.
This multi-center trial will be conducted worldwide. The overall time to participate in this study is up to 36 weeks. After completing the Week 22 Visit procedures, eligible participants may enter a blinded extension study. Participants will make multiple visits to the clinic, and those who do not enter extension study will have a final visit 18 weeks after last dose of study drug for a follow-up assessment. Participants who do not enter the extension study will also participate in a long-term safety follow-up, by telephone, 6 months after the last dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Has demonstrated an inadequate response to, loss of response to, or intolerance of at least 1 of the following agents as defined below:
:
OR
OR
Immunomodulators:
OR
Tumor necrosis factor-alpha (TNF-α) antagonists:
OR
OR
The participant may be receiving a therapeutic dose of the following drugs:
Exclusion Criteria:
Active or latent tuberculosis (TB), as evidenced by a diagnostic TB test performed within 30 days of Screening or during the Screening Period that is positive, defined as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with UC having baseline weight of \<30 kg were randomized to this low dose group and received vedolizumab 100 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
Drug: Vedolizumab
Participants with UC having baseline weight of \<30 kg were randomized to this high dose group and received vedolizumab 200 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
Drug: Vedolizumab
Participants with CD having baseline weight of \<30 kg were randomized to this low dose group and received vedolizumab 100 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
Drug: Vedolizumab
Participants with CD having baseline weight of \<30 kg were randomized to this high dose group and received vedolizumab 200 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
Drug: Vedolizumab
Participants with UC having baseline weight of \>=30 kg were randomized to this low dose group and received vedolizumab 150 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
Drug: Vedolizumab
Participants with UC having baseline weight of \>=30 kg were randomized to this high dose group and received vedolizumab 300 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
Drug: Vedolizumab
Participants with CD having baseline weight of \>=30 kg were randomized to this low dose group and received vedolizumab 150 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
Drug: Vedolizumab
Participants with CD having baseline weight of \>=30 kg were randomized to this low dose group and received vedolizumab 300 mg IV infusion on Day 1 and at Weeks 2, 6 and 14.
Drug: Vedolizumab
Vedolizumab IV infusion.
Also known as: MLN0002, ENTYVIO, KYNTELES
AUCWeek 14: Area Under the Serum Concentration-time Curve at Week 14
Time frame: From Day 43 (Week 6) post-dose up to pre-dose Day 99 (Week 14)
Cav,Week 14: Average Serum Concentration During a Dosing Interval at Week 14
Time frame: From Day 43 (week 6) post-dose up to pre-dose Day 99 (Week 14)
Ctrough,Week 14: Observed Serum Concentration at the End of a Dosing Interval at Week 14
Time frame: At the end of a dosing interval at Week 14
Percentage of UC Participants Who Achieve Clinical Response Based on Complete Mayo Score
Clinical response was defined as a reduction in complete Mayo score of \>= 3 points and \>=30 % from Baseline with an accompanying decrease in rectal bleeding sub-score of \>=1 point(s) or absolute rectal bleeding sub-score of \<= 1 point. Mayo score was used in to assess UC disease activity. It consisted of 4 subscales: stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscale was scored on a scale of 0 to 3, where 0= normal condition and 3 = severe disease condition. The total Mayo score ranged from 0 to 12, with higher scores indicating more severe disease.
Time frame: Baseline (Day 1) and Week 14
Percentage of CD Participants Who Achieve Clinical Response Based on Crohn's Disease Activity Index (CDAI)
Clinical response was defined as \>=70 points decrease from Baseline in CDAI score at Week 14. The CDAI evaluated severity of signs and symptoms of CD. Information was collected on number of liquid stools, intensity of abdominal pain, general well-being, presence of comorbid conditions, use of medications for diarrhea, physical examination, and laboratory, yielding 8 items that were combined with data from a 7-day diary to obtain total CDAI score. Index values of 150 and below were associated with quiescent disease; values above that indicated active disease, values \>=220 indicated moderate to severe disease, and values above 450 were seen with extremely severe disease.
Time frame: Baseline (Day 1) and Week 14
Participants took part in the study at 72 investigative sites in United States, Belgium, Canada, France, Germany, Hungary, Israel, Netherlands, Poland, Ukraine, United Kingdom and European Union from 8 November 2017 to 26 March 2020.
| Milestone | UC: <30 kg Participants, Vedolizumab 100 mg | UC: <30 kg Participants, Vedolizumab 200 mg | CD: <30 kg Participants, Vedolizumab 100 mg | CD: <30 kg Participants, Vedolizumab 200 mg | UC: >=30 kg Participants, Vedolizumab 150 mg | UC: >=30 kg Participants, Vedolizumab 300 mg | CD: >=30 kg Participants, Vedolizumab 150 mg | CD: >=30 kg Participants, Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|
| Started | 10 | 9 | 11 | 10 | 13 | 12 | 12 | 12 |
| Completed | 7 | 7 | 9 | 7 | 11 | 7 | 9 | 10 |
| Not completed | 3 | 2 | 2 | 3 | 2 | 5 | 3 | 2 |
| Withdrew: Adverse event | 2 | 1 | 2 | 1 | 1 | 4 | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Reason not specified | 1 | 0 | 0 | 2 | 1 | 1 | 0 | 0 |
| h*ng/mL | UC: <30 kg Participants, Vedolizumab 100 mg | UC: <30 kg Participants, Vedolizumab 200 mg | CD: <30 kg Participants, Vedolizumab 100 mg | CD: <30 kg Participants, Vedolizumab 200 mg | UC: >=30 kg Participants, Vedolizumab 150 mg | UC: >=30 kg Participants, Vedolizumab 300 mg | CD: >=30 kg Participants, Vedolizumab 150 mg | CD: >=30 kg Participants, Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|
| AUCWeek 14: Area Under the Serum Concentration-time Curve at Week 14 | 1933.5076 ± 1184.36284 | 3231.1001 ± 1152.06628 | 2344.4204 ± 1216.58345 | 3091.7957 ± 1732.34795 | 2449.9433 ± 772.66677 | 4182.4869 ± 1751.87940 | 1865.0004 ± 509.68268 | 3176.6971 ± 928.32630 |
| ng/mL | UC: <30 kg Participants, Vedolizumab 100 mg | UC: <30 kg Participants, Vedolizumab 200 mg | CD: <30 kg Participants, Vedolizumab 100 mg | CD: <30 kg Participants, Vedolizumab 200 mg | UC: >=30 kg Participants, Vedolizumab 150 mg | UC: >=30 kg Participants, Vedolizumab 300 mg | CD: >=30 kg Participants, Vedolizumab 150 mg | CD: >=30 kg Participants, Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|
| Cav,Week 14: Average Serum Concentration During a Dosing Interval at Week 14 | 39.3143 ± 21.34097 | 61.2934 ± 18.14446 | 46.8716 ± 23.07334 | 63.6275 ± 28.29116 | 44.6465 ± 11.48500 | 77.2452 ± 28.49511 | 37.4752 ± 18.26528 | 63.1734 ± 15.08119 |
| ng/mL | UC: <30 kg Participants, Vedolizumab 100 mg | UC: <30 kg Participants, Vedolizumab 200 mg | CD: <30 kg Participants, Vedolizumab 100 mg | CD: <30 kg Participants, Vedolizumab 200 mg | UC: >=30 kg Participants, Vedolizumab 150 mg | UC: >=30 kg Participants, Vedolizumab 300 mg | CD: >=30 kg Participants, Vedolizumab 150 mg | CD: >=30 kg Participants, Vedolizumab 300 mg |
|---|---|---|---|---|---|---|---|---|
| Ctrough,Week 14: Observed Serum Concentration at the End of a Dosing Interval at Week 14 | 9.3100 ± 9.48045 | 10.7226 ± 10.35423 | 8.7395 ± 7.77386 | 10.3685 ± 11.30124 | 16.3645 ± 16.93869 | 21.4860 ± 18.01872 | 3.9006 ± 3.62991 | 7.8310 ± 9.44044 |
Clinical response was defined as a reduction in complete Mayo score of \>= 3 points and \>=30 % from Baseline with an accompanying decrease in rectal bleeding sub-score of \>=1 point(s) or absolute rectal bleeding sub-score of \<= 1 point. Mayo score was used in to assess UC disease activity. It consisted of 4 subscales: stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscale was scored on a scale of 0 to 3, where 0= normal condition and 3 = severe disease condition. The total Mayo score ranged from 0 to 12, with higher scores indicating more severe disease.
| percentage of participants | UC: <30 kg Participants, Vedolizumab 100 mg | UC: <30 kg Participants, Vedolizumab 200 mg | UC: >=30 kg Participants, Vedolizumab 150 mg | UC: >=30 kg Participants, Vedolizumab 300 mg |
|---|---|---|---|---|
| Percentage of UC Participants Who Achieve Clinical Response Based on Complete Mayo Score | 40.0 (12.2 to 73.8) | 66.7 (29.9 to 92.5) | 69.2 (38.6 to 90.9) | 41.7 (15.2 to 72.3) |
Clinical response was defined as \>=70 points decrease from Baseline in CDAI score at Week 14. The CDAI evaluated severity of signs and symptoms of CD. Information was collected on number of liquid stools, intensity of abdominal pain, general well-being, presence of comorbid conditions, use of medications for diarrhea, physical examination, and laboratory, yielding 8 items that were combined with data from a 7-day diary to obtain total CDAI score. Index values of 150 and below were associated with quiescent disease; values above that indicated active disease, values \>=220 indicated moderate to severe disease, and values above 450 were seen with extremely severe disease.
| percentage of participants | CD: <30 kg Participants, Vedolizumab 100 mg | CD: <30 kg Participants, Vedolizumab 200 mg | CD: >=30 kg Participants, Vedolizumab 150 mg | CD: >=30 kg Participants, Vedolizumab 300 mg |
|---|---|---|---|---|
| Percentage of CD Participants Who Achieve Clinical Response Based on Crohn's Disease Activity Index (CDAI) | 63.6 (30.8 to 89.1) | 40.0 (12.2 to 73.8) | 45.5 (16.7 to 76.6) | 33.3 (9.9 to 65.1) |
Collected over From first dose of study drug up to Week 32. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| <30 kg Participants, Vedolizumab 100 mg | 0/17 (0%) | 4/17 (23.5%) | 16/17 (94.1%) |
| <30 kg Participants, Vedolizumab 200 mg | 0/19 (0%) | 6/19 (31.6%) | 13/19 (68.4%) |
| <30 kg Participants, Vedolizumab 100 mg to 200 mg | 0/4 (0%) | 2/4 (50%) | 3/4 (75%) |
| >=30 kg Participants, Vedolizumab 150 mg | 0/18 (0%) | 2/18 (11.1%) | 15/18 (83.3%) |
| >=30 kg Participants, Vedolizumab 300 mg | 0/24 (0%) | 8/24 (33.3%) | 20/24 (83.3%) |
| >=30 kg Participants, Vedolizumab 150 mg to 300 mg | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Event | <30 kg Participants, Vedolizumab 100 mg | <30 kg Participants, Vedolizumab 200 mg | <30 kg Participants, Vedolizumab 100 mg to 200 mg | >=30 kg Participants, Vedolizumab 150 mg | >=30 kg Participants, Vedolizumab 300 mg | >=30 kg Participants, Vedolizumab 150 mg to 300 mg |
|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/17 | 1/19 | 1/4 | 0/18 | 1/24 | 0/6 |
| Abdominal painGastrointestinal disorders | 0/17 | 1/19 | 1/4 | 0/18 | 0/24 | 0/6 |
| ColitisGastrointestinal disorders | 0/17 | 0/19 | 1/4 | 0/18 | 0/24 | 0/6 |
| Decreased appetiteMetabolism and nutrition disorders | 0/17 | 0/19 | 1/4 | 0/18 | 0/24 | 0/6 |
| Viral infectionInfections and infestations | 0/17 | 0/19 | 0/4 | 0/18 | 0/24 | 1/6 |
| Crohn's diseaseGastrointestinal disorders | 0/17 | 3/19 | 0/4 | 1/18 | 2/24 | 0/6 |
| Colitis ulcerativeGastrointestinal disorders | 0/17 | 2/19 | 0/4 | 1/18 | 3/24 | 0/6 |
| Clostridium difficile infectionInfections and infestations | 1/17 | 0/19 | 0/4 | 0/18 | 0/24 | 0/6 |
| Pelvic abscessInfections and infestations | 1/17 | 0/19 | 0/4 | 0/18 | 0/24 | 0/6 |
| VaricellaInfections and infestations | 1/17 | 0/19 | 0/4 | 0/18 | 0/24 | 0/6 |
| Event | <30 kg Participants, Vedolizumab 100 mg | <30 kg Participants, Vedolizumab 200 mg | <30 kg Participants, Vedolizumab 100 mg to 200 mg | >=30 kg Participants, Vedolizumab 150 mg | >=30 kg Participants, Vedolizumab 300 mg | >=30 kg Participants, Vedolizumab 150 mg to 300 mg |
|---|---|---|---|---|---|---|
| VomitingGastrointestinal disorders | 1/17 | 1/19 | 2/4 | 1/18 | 0/24 | 0/6 |
| DiarrhoeaGastrointestinal disorders | 0/17 | 0/19 | 2/4 | 0/18 | 1/24 | 0/6 |
| NauseaGastrointestinal disorders | 1/17 | 0/19 | 0/4 | 0/18 | 0/24 | 2/6 |
| HeadacheNervous system disorders | 1/17 | 2/19 | 0/4 | 2/18 | 3/24 | 2/6 |
| DizzinessNervous system disorders | 1/17 | 0/19 | 0/4 | 0/18 | 0/24 | 2/6 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/17 | 2/19 | 0/4 | 0/18 | 1/24 | 2/6 |
| Abdominal painGastrointestinal disorders | 5/17 | 3/19 | 1/4 | 0/18 | 1/24 | 0/6 |
| Abdominal distensionGastrointestinal disorders | 0/17 | 1/19 | 1/4 | 1/18 | 0/24 | 0/6 |
| Abnormal faecesGastrointestinal disorders | 0/17 | 0/19 | 1/4 | 0/18 | 0/24 | 0/6 |
| Anal fissureGastrointestinal disorders | 0/17 | 0/19 | 1/4 | 0/18 | 0/24 | 0/6 |
Randomized Set included all participants who are randomized into the study regardless whether they received any dose of study drug or not.
| Age, Continuous(years) | UC: <30 kg Participants, Vedolizumab 100 mg | UC: <30 kg Participants, Vedolizumab 200 mg | CD: <30 kg Participants, Vedolizumab 100 mg | CD: <30 kg Participants, Vedolizumab 200 mg | UC: >=30 kg Participants, Vedolizumab 150 mg | UC: >=30 kg Participants, Vedolizumab 300 mg | CD: >=30 kg Participants, Vedolizumab 150 mg | CD: >=30 kg Participants, Vedolizumab 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 7.0 (3 to 12) | 8.0 (2 to 12) | 7.4 (2 to 12) | 8.1 (3 to 12) | 12.4 (8 to 17) | 13.9 (9 to 17) | 13.4 (10 to 17) | 14.3 (11 to 17) | 10.56 (2 to 17) |
| Sex: Female, Male(Participants) | UC: <30 kg Participants, Vedolizumab 100 mg | UC: <30 kg Participants, Vedolizumab 200 mg | CD: <30 kg Participants, Vedolizumab 100 mg | CD: <30 kg Participants, Vedolizumab 200 mg | UC: >=30 kg Participants, Vedolizumab 150 mg | UC: >=30 kg Participants, Vedolizumab 300 mg | CD: >=30 kg Participants, Vedolizumab 150 mg | CD: >=30 kg Participants, Vedolizumab 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 4 | 4 | 5 | 5 | 6 | 8 | 3 | 39 |
| Male | 6 | 5 | 7 | 5 | 8 | 6 | 4 | 9 | 50 |
| Ethnicity (NIH/OMB)(Participants) | UC: <30 kg Participants, Vedolizumab 100 mg | UC: <30 kg Participants, Vedolizumab 200 mg | CD: <30 kg Participants, Vedolizumab 100 mg | CD: <30 kg Participants, Vedolizumab 200 mg | UC: >=30 kg Participants, Vedolizumab 150 mg | UC: >=30 kg Participants, Vedolizumab 300 mg | CD: >=30 kg Participants, Vedolizumab 150 mg | CD: >=30 kg Participants, Vedolizumab 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 9 |
| Not Hispanic or Latino | 10 | 7 | 7 | 8 | 12 | 11 | 11 | 12 | 78 |
| Unknown or Not Reported | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | UC: <30 kg Participants, Vedolizumab 100 mg | UC: <30 kg Participants, Vedolizumab 200 mg | CD: <30 kg Participants, Vedolizumab 100 mg | CD: <30 kg Participants, Vedolizumab 200 mg | UC: >=30 kg Participants, Vedolizumab 150 mg | UC: >=30 kg Participants, Vedolizumab 300 mg | CD: >=30 kg Participants, Vedolizumab 150 mg | CD: >=30 kg Participants, Vedolizumab 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 2 | 1 | 0 | 2 | 0 | 2 | 0 | 8 |
| White | 7 | 7 | 7 | 9 | 11 | 10 | 9 | 11 | 71 |
| More than one race | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 3 |
| Unknown or Not Reported | 2 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 5 |
| Region of Enrollment(Participants) | UC: <30 kg Participants, Vedolizumab 100 mg | UC: <30 kg Participants, Vedolizumab 200 mg | CD: <30 kg Participants, Vedolizumab 100 mg | CD: <30 kg Participants, Vedolizumab 200 mg | UC: >=30 kg Participants, Vedolizumab 150 mg | UC: >=30 kg Participants, Vedolizumab 300 mg | CD: >=30 kg Participants, Vedolizumab 150 mg | CD: >=30 kg Participants, Vedolizumab 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Belgium | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 5 |
| France | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hungary | 1 | 0 | 1 | 1 | 3 | 4 | 4 | 3 | 17 |
| Poland | 2 | 1 | 4 | 2 | 1 | 0 | 2 | 3 | 15 |
| United Kingdom | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 2 | 6 |
| Ukraine | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Israel | 3 | 2 | 0 | 2 | 3 | 2 | 0 | 1 | 13 |
| Canada | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| United States | 2 | 5 | 4 | 4 | 5 | 5 | 2 | 2 | 29 |
| Height(cm) | UC: <30 kg Participants, Vedolizumab 100 mg | UC: <30 kg Participants, Vedolizumab 200 mg | CD: <30 kg Participants, Vedolizumab 100 mg | CD: <30 kg Participants, Vedolizumab 200 mg | UC: >=30 kg Participants, Vedolizumab 150 mg | UC: >=30 kg Participants, Vedolizumab 300 mg | CD: >=30 kg Participants, Vedolizumab 150 mg | CD: >=30 kg Participants, Vedolizumab 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 119.59 (82.7 to 146.0) | 122.39 (84.9 to 143.0) | 120.58 (83.5 to 146.0) | 124.67 (96.5 to 137.6) | 153.11 (128.0 to 176.1) | 160.03 (138.3 to 185.4) | 157.85 (134.3 to 182.5) | 157.98 (141.9 to 181.5) | 139.53 (82.7 to 185.4) |
| Weight(kg) | UC: <30 kg Participants, Vedolizumab 100 mg | UC: <30 kg Participants, Vedolizumab 200 mg | CD: <30 kg Participants, Vedolizumab 100 mg | CD: <30 kg Participants, Vedolizumab 200 mg | UC: >=30 kg Participants, Vedolizumab 150 mg | UC: >=30 kg Participants, Vedolizumab 300 mg | CD: >=30 kg Participants, Vedolizumab 150 mg | CD: >=30 kg Participants, Vedolizumab 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 22.38 (12.8 to 29.6) | 23.23 (10.2 to 29.8) | 22.06 (12.0 to 29.9) | 23.37 (14.3 to 30.0) | 46.22 (30.3 to 75.9) | 53.98 (32.0 to 78.9) | 51.53 (31.4 to 79.0) | 45.89 (33.9 to 68.0) | 36.08 (10.2 to 79.0) |
| Body Mass Index (BMI)(kg/m^2) | UC: <30 kg Participants, Vedolizumab 100 mg | UC: <30 kg Participants, Vedolizumab 200 mg | CD: <30 kg Participants, Vedolizumab 100 mg | CD: <30 kg Participants, Vedolizumab 200 mg | UC: >=30 kg Participants, Vedolizumab 150 mg | UC: >=30 kg Participants, Vedolizumab 300 mg | CD: >=30 kg Participants, Vedolizumab 150 mg | CD: >=30 kg Participants, Vedolizumab 300 mg | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 15.63 (13.4 to 18.7) | 15.29 (12.4 to 20.0) | 15.04 (13.5 to 17.2) | 14.93 (12.4 to 16.9) | 19.51 (16.4 to 26.5) | 20.76 (16.7 to 27.1) | 20.50 (14.4 to 24.5) | 18.26 (15.8 to 25.9) | 17.49 (12.4 to 27.1) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Nov 2017 to primary completion in Mar 2020, 28 months.
Results were first posted in Dec 2020, 8 months after primary completion.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 28 months is close to that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vedolizumab